Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Selective collection of iron-rich dust particles by natural Trichodesmium colonies.

Kessler N, Armoza-Zvuloni R, Wang S, Basu S, Weber PK, Stuart RK, Shaked Y.

ISME J. 2019 Sep 24. doi: 10.1038/s41396-019-0505-x. [Epub ahead of print]

PMID:
31551530
2.

Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia.

DeAngelo DJ, Walker AR, Schlenk RF, Sierra J, Medeiros BC, Ocio EM, Röllig C, Strickland SA, Thol F, Valera SZ, Dasgupta K, Berkowitz N, Stuart RK.

Leuk Res. 2019 Aug 1;85:106197. doi: 10.1016/j.leukres.2019.106197. [Epub ahead of print]

PMID:
31541945
3.

A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.

Lin TL, Newell LF, Stuart RK, Michaelis LC, Rubenstein E, Pentikis HS, Callahan T, Alvarez D, Liboiron BD, Mayer LD, Wang Q, Banerjee K, Louie AC.

Cancer Chemother Pharmacol. 2019 Jul;84(1):163-173. doi: 10.1007/s00280-019-03856-9. Epub 2019 May 16.

4.

Reaction of O2 with a diiron protein generates a mixed-valent Fe2+/Fe3+ center and peroxide.

Bradley JM, Svistunenko DA, Pullin J, Hill N, Stuart RK, Palenik B, Wilson MT, Hemmings AM, Moore GR, Le Brun NE.

Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2058-2067. doi: 10.1073/pnas.1809913116. Epub 2019 Jan 18.

5.

Pervasive iron limitation at subsurface chlorophyll maxima of the California Current.

Hogle SL, Dupont CL, Hopkinson BM, King AL, Buck KN, Roe KL, Stuart RK, Allen AE, Mann EL, Johnson ZI, Barbeau KA.

Proc Natl Acad Sci U S A. 2018 Dec 26;115(52):13300-13305. doi: 10.1073/pnas.1813192115. Epub 2018 Dec 10.

6.

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.

Chhabra S, Ahn KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, Litzow MR, Nathan S, Olsson RF, Pawarode A, Ringden O, Rowe JM, Saad A, Savani BN, Schouten HC, Seo S, Shah NN, Solh M, Stuart RK, Ustun C, Woolfrey AE, Yared JA, Alyea EP, Kalaycio ME, Popat U, Sobecks RM, Saber W.

Blood Adv. 2018 Nov 13;2(21):2922-2936. doi: 10.1182/bloodadvances.2018024844.

7.

Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.

Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh MM, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK.

Biol Blood Marrow Transplant. 2019 Jan;25(1):73-85. doi: 10.1016/j.bbmt.2018.08.018. Epub 2018 Aug 25.

PMID:
30153491
8.

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.

Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC.

J Clin Oncol. 2018 Sep 10;36(26):2684-2692. doi: 10.1200/JCO.2017.77.6112. Epub 2018 Jul 19.

9.

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM.

N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2.

10.

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK.

Haematologica. 2018 Nov;103(11):e514-e518. doi: 10.3324/haematol.2018.191361. Epub 2018 May 24. No abstract available.

11.

A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.

Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J, Westervelt P, DiPersio JF, Hillman TM, Silver N, Szarek M, Gorelik L, Lowdell MW, Rowinsky E.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1581-1589. doi: 10.1016/j.bbmt.2018.03.019. Epub 2018 Mar 27.

12.

Feathermoss and epiphytic Nostoc cooperate differently: expanding the spectrum of plant-cyanobacteria symbiosis.

Warshan D, Espinoza JL, Stuart RK, Richter RA, Kim SY, Shapiro N, Woyke T, C Kyrpides N, Barry K, Singan V, Lindquist E, Ansong C, Purvine SO, M Brewer H, Weyman PD, Dupont CL, Rasmussen U.

ISME J. 2017 Dec;11(12):2821-2833. doi: 10.1038/ismej.2017.134. Epub 2017 Aug 11.

13.

Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape.

Sedov V, Stuart RK.

Ther Adv Hematol. 2017 Jun;8(6):185-195. doi: 10.1177/2040620717703012. Epub 2017 Apr 21. Review.

14.

Copper toxicity response influences mesotrophic Synechococcus community structure.

Stuart RK, Bundy R, Buck K, Ghassemain M, Barbeau K, Palenik B.

Environ Microbiol. 2017 Feb;19(2):756-769. doi: 10.1111/1462-2920.13630. Epub 2017 Jan 26.

PMID:
27884049
15.

Permanent draft genome of strain ESFC-1: ecological genomics of a newly discovered lineage of filamentous diazotrophic cyanobacteria.

Everroad RC, Stuart RK, Bebout BM, Detweiler AM, Lee JZ, Woebken D, Prufert-Bebout L, Pett-Ridge J.

Stand Genomic Sci. 2016 Aug 24;11(1):53. doi: 10.1186/s40793-016-0174-6. eCollection 2016.

16.

Light Regimes Shape Utilization of Extracellular Organic C and N in a Cyanobacterial Biofilm.

Stuart RK, Mayali X, Boaro AA, Zemla A, Everroad RC, Nilson D, Weber PK, Lipton M, Bebout BM, Pett-Ridge J, Thelen MP.

MBio. 2016 Jun 28;7(3). pii: e00650-16. doi: 10.1128/mBio.00650-16.

17.

Cyanobacterial reuse of extracellular organic carbon in microbial mats.

Stuart RK, Mayali X, Lee JZ, Craig Everroad R, Hwang M, Bebout BM, Weber PK, Pett-Ridge J, Thelen MP.

ISME J. 2016 May;10(5):1240-51. doi: 10.1038/ismej.2015.180. Epub 2015 Oct 23.

18.

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM.

Lancet Oncol. 2015 Sep;16(9):1025-1036. doi: 10.1016/S1470-2045(15)00201-6. Epub 2015 Jul 30.

19.

Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.

Stone RM, Mazzola E, Neuberg D, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Egyed M, Horst HA, Selleslag D, Solomon SR, Venugopal P, Lundberg AS, Powell B.

J Clin Oncol. 2015 Apr 10;33(11):1252-7. doi: 10.1200/JCO.2014.57.0952. Epub 2015 Mar 2.

PMID:
25732165
20.

Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumors.

God JM, Cameron C, Figueroa J, Amria S, Hossain A, Kempkes B, Bornkamm GW, Stuart RK, Blum JS, Haque A.

J Immunol. 2015 Feb 15;194(4):1434-45. doi: 10.4049/jimmunol.1402382. Epub 2015 Jan 16.

21.

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.

Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP, Damon LE, Powell BL, Lindeman N, Steensma DP, Wadleigh M, DeAngelo DJ, Neuberg D, Stone RM, Ebert BL.

Blood. 2015 Feb 26;125(9):1367-76. doi: 10.1182/blood-2014-11-610543. Epub 2014 Dec 30.

22.

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.

Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi F.

Br J Haematol. 2015 Mar;168(6):796-805. doi: 10.1111/bjh.13214. Epub 2014 Nov 17.

23.

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.

Lancet JE, Roboz GJ, Cripe LD, Michelson GC, Fox JA, Leavitt RD, Chen T, Hawtin R, Craig AR, Ravandi F, Maris MB, Stuart RK, Karp JE.

Haematologica. 2015 Feb;100(2):231-7. doi: 10.3324/haematol.2014.114769. Epub 2014 Nov 7.

24.

Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.

Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, Roberts JD, Sullivan D, Grant S.

Clin Cancer Res. 2014 Nov 15;20(22):5652-62. doi: 10.1158/1078-0432.CCR-14-0805. Epub 2014 Sep 23.

25.

Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Costa LJ, Fanning SR, Stephenson J Jr, Afrin LB, Kistner-Griffin E, Bentz TA, Stuart RK.

Leuk Lymphoma. 2015 Mar;56(3):645-9. doi: 10.3109/10428194.2014.935369.

PMID:
25130476
26.

Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor.

Schade H, Chhabra S, Kang Y, Stuart RK, Edwards KH, Kramer C, Butcher C, Littleton A, Schneider M, Budisavljevic MN, Costa LJ.

Transfusion. 2014 Dec;54(12):3131-7. doi: 10.1111/trf.12761. Epub 2014 Jun 19.

PMID:
24947954
27.

Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification.

Costa LJ, Nista EJ, Buadi FK, Lacy MQ, Dispenzieri A, Kramer CP, Edwards KH, Kang Y, Gertz MA, Stuart RK, Kumar S.

Biol Blood Marrow Transplant. 2014 Feb;20(2):222-8. doi: 10.1016/j.bbmt.2013.11.003. Epub 2013 Nov 6.

28.

Impact of DNA damaging agents on genome-wide transcriptional profiles in two marine Synechococcus species.

Tetu SG, Johnson DA, Varkey D, Phillippy K, Stuart RK, Dupont CL, Hassan KA, Palenik B, Paulsen IT.

Front Microbiol. 2013 Aug 16;4:232. doi: 10.3389/fmicb.2013.00232. eCollection 2013.

29.

Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there?

Mims A, Stuart RK.

Curr Hematol Malig Rep. 2013 Jun;8(2):156-62. doi: 10.1007/s11899-013-0158-1. Review.

PMID:
23640069
30.

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, Larson RA, Erba HP, Stiff PJ, Stuart RK, Walter RB, Tallman MS, Stenke L, Appelbaum FR.

Blood. 2013 Jun 13;121(24):4854-60. doi: 10.1182/blood-2013-01-466706. Epub 2013 Apr 16.

31.

Genomic island genes in a coastal marine Synechococcus strain confer enhanced tolerance to copper and oxidative stress.

Stuart RK, Brahamsha B, Busby K, Palenik B.

ISME J. 2013 Jun;7(6):1139-49. doi: 10.1038/ismej.2012.175. Epub 2013 Jan 24.

32.

Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange.

Costa LJ, Abbas J, Ortiz-Cruz KL, Kang Y, Stuart RK.

Eur J Haematol. 2012 Nov;89(5):432-4. doi: 10.1111/ejh.12008. Epub 2012 Sep 13. No abstract available.

PMID:
22971164
33.

Vosaroxin : a novel antineoplastic quinolone.

Abbas JA, Stuart RK.

Expert Opin Investig Drugs. 2012 Aug;21(8):1223-33. doi: 10.1517/13543784.2012.699038. Epub 2012 Jun 23. Review.

PMID:
22724917
34.

Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients.

Butler C, Wolff DJ, Kang Y, Stuart RK, Costa LJ.

Leuk Lymphoma. 2012 Dec;53(12):2444-8. doi: 10.3109/10428194.2012.691483. Epub 2012 May 31.

PMID:
22574971
35.

Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.

Costa LJ, Abbas J, Hogan KR, Kramer C, McDonald K, Butcher CD, Littleton A, Shoptaw K, Kang Y, Stuart RK.

Bone Marrow Transplant. 2012 Nov;47(11):1403-8. doi: 10.1038/bmt.2012.60. Epub 2012 Apr 9.

PMID:
22484324
36.

Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.

Costa LJ, Kramer C, Hogan KR, Butcher CD, Littleton AL, Shoptaw KB, Kang Y, Stuart RK.

Transfusion. 2012 Nov;52(11):2375-81. doi: 10.1111/j.1537-2995.2012.03579.x. Epub 2012 Mar 8.

PMID:
22404694
37.

Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents.

Rivell GL, Brunson CY, Milligan L, Stuart RK, Costa LJ.

Am J Hematol. 2011 Aug;86(8):699-701. doi: 10.1002/ajh.22054. Epub 2011 May 31. No abstract available.

38.

Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.

Holkova B, Perkins EB, Ramakrishnan V, Tombes MB, Shrader E, Talreja N, Wellons MD, Hogan KT, Roodman GD, Coppola D, Kang L, Dawson J, Stuart RK, Peer C, Figg WD Sr, Kolla S, Doyle A, Wright J, Sullivan DM, Roberts JD, Grant S.

Clin Cancer Res. 2011 May 15;17(10):3388-97. doi: 10.1158/1078-0432.CCR-10-2876. Epub 2011 Mar 29.

40.

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.

Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Wiktor-Jedrzejczak W, Juliusson G, Litzow MR, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Smith BD.

Blood. 2011 Mar 24;117(12):3294-301. doi: 10.1182/blood-2010-08-301796. Epub 2011 Jan 26.

41.

A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.

Lancet JE, Duong VH, Winton EF, Stuart RK, Burton M, Zhang S, Cubitt C, Blaskovich MA, Wright JJ, Sebti S, Sullivan DM.

Clin Cancer Res. 2011 Mar 1;17(5):1140-6. doi: 10.1158/1078-0432.CCR-10-1878. Epub 2011 Jan 13.

42.

Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients.

Miller AN, Glode A, Hogan KR, Schaub C, Kramer C, Stuart RK, Costa LJ.

Biol Blood Marrow Transplant. 2011 Aug;17(8):1176-81. doi: 10.1016/j.bbmt.2010.12.700. Epub 2010 Dec 23.

43.

Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.

Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, Lancet JE, Coutre SE, Stuart RK, Mims MP, Stiff PJ, Appelbaum FR.

Br J Haematol. 2010 Dec;151(5):430-4.

44.

Helical tomotherapy for extramedullary hematopoiesis involving the pericardium in a patient with chronic myeloid leukemia.

Toms DR, Cannick L, Stuart RK, Jenrette JM, Terwiliger L.

Jpn J Radiol. 2010 Jul;28(6):476-8. doi: 10.1007/s11604-010-0452-y. Epub 2010 Jul 27.

PMID:
20661700
45.

Overcoming HLA-DPB1 donor specific antibody-mediated haematopoietic graft failure.

Costa LJ, Moussa O, Bray RA, Stuart RK.

Br J Haematol. 2010 Oct;151(1):94-6. doi: 10.1111/j.1365-2141.2010.08305.x. Epub 2010 Jul 16. No abstract available.

PMID:
20636435
46.

Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization.

Costa LJ, Miller AN, Alexander ET, Hogan KR, Shabbir M, Schaub C, Stuart RK.

Bone Marrow Transplant. 2011 Apr;46(4):523-8. doi: 10.1038/bmt.2010.170. Epub 2010 Jul 12.

PMID:
20622909
47.

Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.

Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK.

Bone Marrow Transplant. 2011 Jan;46(1):64-9. doi: 10.1038/bmt.2010.78. Epub 2010 Apr 12.

PMID:
20383210
48.

Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.

Schiller GJ, O'Brien SM, Pigneux A, Deangelo DJ, Vey N, Kell J, Solomon S, Stuart RK, Karsten V, Cahill AL, Albitar MX, Giles FJ.

J Clin Oncol. 2010 Feb 10;28(5):815-21. doi: 10.1200/JCO.2009.24.2008. Epub 2009 Dec 21.

PMID:
20026800
49.

Hematopoietic stem cell origin of human fibroblasts: cell culture studies of female recipients of gender-mismatched stem cell transplantation and patients with chronic myelogenous leukemia.

Shirai K, Sera Y, Bulkeley W, Mehrotra M, Moussa O, LaRue AC, Watson DK, Stuart RK, Lazarchick J, Ogawa M.

Exp Hematol. 2009 Dec;37(12):1464-71. doi: 10.1016/j.exphem.2009.09.008. Epub 2009 Sep 26.

50.

Overexpression of nucleolin in engrafted acute myelogenous leukemia cells.

Gattoni-Celli S, Buckner CL, Lazarchick J, Stuart RK, Fernandes DJ.

Am J Hematol. 2009 Aug;84(8):535-8. doi: 10.1002/ajh.21461. No abstract available. Erratum in: Am J Hematol. 2009 Sep;84(9):626.

Supplemental Content

Loading ...
Support Center